[go: up one dir, main page]

PE20110385A1 - Anticuerpo de dominio (dab) que se une a cd28 y no reacciona en forma cruzada con ctla4 - Google Patents

Anticuerpo de dominio (dab) que se une a cd28 y no reacciona en forma cruzada con ctla4

Info

Publication number
PE20110385A1
PE20110385A1 PE2011000053A PE2011000053A PE20110385A1 PE 20110385 A1 PE20110385 A1 PE 20110385A1 PE 2011000053 A PE2011000053 A PE 2011000053A PE 2011000053 A PE2011000053 A PE 2011000053A PE 20110385 A1 PE20110385 A1 PE 20110385A1
Authority
PE
Peru
Prior art keywords
seq
dab
domain antibody
ctla4
joins
Prior art date
Application number
PE2011000053A
Other languages
English (en)
Inventor
Steven G Nadler
Suzanne J Suchard
Steve Holmes
Olga Ignatovich
Christopher James Plummer
Steve Daryl Grant
Murray Mckinnon
Brendan Classon
Original Assignee
Bristol Myers Squibb Co
Domantis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41226147&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20110385(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co, Domantis Ltd filed Critical Bristol Myers Squibb Co
Publication of PE20110385A1 publication Critical patent/PE20110385A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)

Abstract

REFERIDA A UN ANTICUERPO DE DOMINIO (dAb) QUE SE UNE A CD28 Y PREVIENE LA UNION DE CD28 A CD80 Y/O CD86, DONDE EL dAb COMPRENDE: a) UNA SECUENCIA DE CDR1 AL MENOS 50% IDENTICA A UNA SECUENCIA DE CDR1 TAL COMO SEQ ID NO: 484, SEQ ID NO: 487, SEQ ID NO: 490, ENTRE OTRAS, b) UNA SECUENCIA DE CDR2 AL MENOS 50% IDENTICA A UNA SECUENCIA DE CDR2 TAL COMO SEQ ID NO: 485, SEQ ID NO: 488, SEQ ID NO: 488, ENTRE OTRAS, c) UNA SECUENCIA DE CDR3 AL MENOS 50% IDENTICA A UNA SECUENCIA DE CDR3 TAL COMO SEQ ID NO: 486, SEQ ID NO: 489, SEQ ID NO: 492, ENTRE OTRAS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS ANTICUERPOS SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES AUTOINMUNES O ENFERMEDADES RELACIONADAS CON INJERTOS
PE2011000053A 2008-07-18 2009-07-17 Anticuerpo de dominio (dab) que se une a cd28 y no reacciona en forma cruzada con ctla4 PE20110385A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8207808P 2008-07-18 2008-07-18
US16212109P 2009-03-20 2009-03-20

Publications (1)

Publication Number Publication Date
PE20110385A1 true PE20110385A1 (es) 2011-06-22

Family

ID=41226147

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2011000053A PE20110385A1 (es) 2008-07-18 2009-07-17 Anticuerpo de dominio (dab) que se une a cd28 y no reacciona en forma cruzada con ctla4
PE2014000192A PE20140852A1 (es) 2008-07-18 2009-07-17 Composiciones monovalentes para union a cd28

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2014000192A PE20140852A1 (es) 2008-07-18 2009-07-17 Composiciones monovalentes para union a cd28

Country Status (29)

Country Link
US (6) US8168759B2 (es)
EP (2) EP2321352B1 (es)
JP (3) JP5675608B2 (es)
KR (2) KR101791372B1 (es)
CN (2) CN105936648B (es)
AR (1) AR072571A1 (es)
AU (1) AU2009270726B2 (es)
CA (1) CA2731220C (es)
CL (2) CL2011000117A1 (es)
CO (1) CO6341641A2 (es)
CY (1) CY1121796T1 (es)
DK (2) DK2700651T3 (es)
EA (1) EA024585B1 (es)
ES (2) ES2562629T3 (es)
HR (2) HRP20160329T1 (es)
HU (2) HUE029982T2 (es)
IL (2) IL210413A (es)
LT (1) LT2700651T (es)
ME (1) ME02396B (es)
MX (1) MX2011000501A (es)
NZ (1) NZ590343A (es)
PE (2) PE20110385A1 (es)
PL (2) PL2700651T3 (es)
PT (2) PT2700651T (es)
RS (2) RS58904B1 (es)
SI (2) SI2321352T1 (es)
SM (2) SMT201900367T1 (es)
TW (2) TW201336510A (es)
WO (1) WO2010009391A1 (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE045710T2 (hu) 2005-05-18 2020-01-28 Ablynx Nv Javított, alfa tumor nekrózis faktor elleni nanobodies
US20110097339A1 (en) * 2008-07-18 2011-04-28 Domantis Limited Compositions monovalent for CD28 binding and methods of use
CN105936648B (zh) * 2008-07-18 2020-06-16 百时美施贵宝公司 Cd28结合为单价的组合物及使用方法
US8946128B2 (en) * 2009-02-25 2015-02-03 Nextera As Signal sequence-independent pIX phage display
FR2951176A1 (fr) * 2009-10-09 2011-04-15 Tcl Pharma Ligands monovalents du recepteur cd28 humain
LT2536764T (lt) 2010-02-18 2018-10-25 Ose Immunotherapeutics Anti-cd28 humanizuoti antikūnai
EP2361935A1 (en) * 2010-02-18 2011-08-31 TcL Pharma Anti-CD28 humanized antibodies
MX336540B (es) 2010-06-08 2016-01-22 Genentech Inc Conjugados y anticuerpos manipulados geneticamente con cisteina.
JP5768022B2 (ja) * 2012-03-19 2015-08-26 株式会社東芝 メモリコントローラ、記憶装置、誤り訂正装置および誤り訂正方法
WO2014120916A1 (en) 2013-02-01 2014-08-07 Bristol-Myers Squibb Company Pegylated domain antibodies monovalent for cd28 binding and methods of use
RU2714967C2 (ru) * 2013-12-27 2020-02-21 Чугаи Сейяку Кабусики Кайся Способ очистки антител с низкой изоэлектрической точкой
AU2015231180B2 (en) * 2014-03-19 2017-06-15 Bristol-Myers Squibb Company Methods of treating transplant rejection using a domain antibody directed against CD40L
EP3191521A2 (en) 2014-09-12 2017-07-19 F. Hoffmann-La Roche AG Cysteine engineered antibodies and conjugates
WO2016054218A1 (en) 2014-09-30 2016-04-07 Bristol-Myers Squibb Company Methods of treating systemic lupus erythematosus using a domain antibody directed against cd28
WO2017160975A1 (en) 2016-03-16 2017-09-21 Bristol-Myers Squibb Company Methods of diagnosing and treating lupus
JP2020508436A (ja) 2016-12-07 2020-03-19 プロジェニティ， インコーポレイテッド 胃腸管の検出方法、装置およびシステム
CA3054632A1 (en) 2017-03-30 2018-10-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
CN110770255B (zh) 2017-04-11 2025-07-01 因荷布瑞克斯生物科学公司 具有受限cd3结合的多特异性多肽构建体及其使用方法
BR112020018279A2 (pt) 2018-03-15 2020-12-29 Biond Biologics Ltd. Métodos e composições para diminuir receptor cd28 imunológico solúvel
CN112218686A (zh) 2018-04-11 2021-01-12 印希比股份有限公司 具有受限cd3结合的多特异性多肽构建体以及相关方法和用途
WO2019241730A2 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
EP3845652A4 (en) 2018-06-22 2022-04-13 JUNTEN BIO Co., Ltd. ANTIBODIES FOR INDUCING IMMUNTOLERANCE, INDUCED LYMPHOCYTE AND THERAPEUTIC METHOD WITH CELL THERAPY AGENT USING INDUCED LYMPHOCYTE
US10954508B2 (en) * 2018-07-08 2021-03-23 Specifica Inc. Antibody libraries with maximized antibody developability characteristics
US12195533B2 (en) 2018-07-24 2025-01-14 Inhibrx Biosciences, Inc. Multispecific polypeptide constructs containing a constrained CD3 binding domain and a receptor binding region and methods of using the same
CN112534263A (zh) 2018-08-03 2021-03-19 百时美施贵宝公司 用于检测抗药抗体的方法
AU2019383976B2 (en) 2018-11-19 2025-07-03 Bt Bidco, Inc. Methods and devices for treating a disease with biotherapeutics
EP3938397A1 (en) * 2019-03-14 2022-01-19 Biond Biologics Ltd. Small shedding blocking agents
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
ES2821599A1 (es) * 2019-10-24 2021-04-26 Univ Del Pais Vasco / Euskal Herriko Unibertsitatea Compuestos y metodos para el tratamiento de la enfermedad de alzheimer
CA3160216A1 (en) * 2019-12-02 2021-06-10 Motti HAKIM Use of mmp inhibition
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
IL294879A (en) * 2020-01-29 2022-09-01 Inhibrx Inc Cd28 single domain antibodies and multivalent and multispecific constructs thereof
US20230355804A1 (en) 2020-06-29 2023-11-09 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
WO2022031695A1 (en) * 2020-08-04 2022-02-10 Exelixis, Inc. Pd-l1 binding agents and uses thereof
CA3214085A1 (en) 2021-03-31 2022-10-06 Darby Rye Schmidt Thanotransmission polypeptides and their use in treating cancer
US20240316104A1 (en) 2021-06-29 2024-09-26 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
AU2022341016A1 (en) * 2021-09-06 2024-04-18 Biond Biologics Ltd. Cd28 shedding blocking agents
AR129203A1 (es) * 2022-05-04 2024-07-31 Janux Therapeutics Inc Anticuerpos multiespecíficos activados por tumores para dirigirse a cd28 y pd-l1, y métodos para usarlos
WO2023215498A2 (en) * 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
WO2023215560A1 (en) 2022-05-05 2023-11-09 Atoosa Corporation Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp)
EP4572772A1 (en) 2022-08-17 2025-06-25 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
IL319680A (en) 2022-10-06 2025-05-01 Bicara Therapeutics Inc Multispecific proteins and related methods
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2024211211A1 (en) 2023-04-03 2024-10-10 Regeneron Pharmaceuticals, Inc. Methods of improving transplant survival using il-2 receptor gamma chain antibodies
WO2024249954A1 (en) 2023-05-31 2024-12-05 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839295A (en) 1984-06-08 1989-06-13 Pierce Chemical Company Measurement of protein using bicinchoninic acid
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2046830C (en) 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
ES2325541T3 (es) 1992-08-21 2009-09-08 Vrije Universiteit Brussel Inmunoglobulinas desprovistas de cadenas ligeras.
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US5922545A (en) 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
GB9416721D0 (en) 1994-08-18 1994-10-12 Short Brothers Plc A bias yarn assembly forming device
WO1996028143A1 (de) 1995-03-10 1996-09-19 Boehringer Mannheim Gmbh Polypeptid-enthaltende pharmazeutische darreichungsformen in form von mikropartikeln und verfahren zu deren herstellung
JP4436457B2 (ja) 1995-08-18 2010-03-24 モルフォシス アイピー ゲーエムベーハー 蛋白質／（ポリ）ペプチドライブラリー
EP0988321A2 (en) 1997-06-20 2000-03-29 Innogenetics N.V. B7-binding molecules for treating immune diseases
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
JP2002512182A (ja) 1998-04-20 2002-04-23 ジェンザイム・コーポレーション ポリマーブレンドから蛋白質のドラックデリバリー
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
EP1179013A1 (en) 1999-05-14 2002-02-13 Medical Research Council Protein scaffold and its use to multimerise monomeric polypeptides
US20020006403A1 (en) * 1999-12-14 2002-01-17 Xue-Zhong Yu CD28-specific antibody compositions for use in methods of immunosuppression
EP1345969B1 (fr) * 2000-12-26 2010-08-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anticorps anti-cd28
WO2002066059A2 (en) 2001-02-16 2002-08-29 Genetics Institute, Llc Agents that specifically block cd28-mediated signaling and uses therefor
US20080095774A1 (en) * 2001-02-16 2008-04-24 Wyeth Agents and Methods for Specifically Blocking CD28-Mediated Signaling
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
JP4303105B2 (ja) 2001-06-28 2009-07-29 ドマンティス リミテッド 二重特異性リガンドとその利用
EP2277913A3 (en) 2001-08-10 2012-08-08 Aberdeen University Antigen binding domains from fish
WO2003031611A2 (en) 2001-10-05 2003-04-17 Cangene Corporation Phagemid display system
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
DE10156482A1 (de) * 2001-11-12 2003-05-28 Gundram Jung Bispezifisches Antikörper-Molekül
EP1517921B1 (en) 2002-06-28 2006-06-07 Domantis Limited Dual specific ligands with increased serum half-life
NZ540194A (en) 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
JP2006523090A (ja) 2002-12-27 2006-10-12 ドマンティス リミテッド リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体
WO2004106381A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
US20050164301A1 (en) 2003-10-24 2005-07-28 Avidia Research Institute LDL receptor class A and EGF domain monomers and multimers
CN100376599C (zh) * 2004-04-01 2008-03-26 北京安波特基因工程技术有限公司 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体
CN101061140B (zh) * 2004-09-17 2015-07-01 多曼蒂斯有限公司 单价结合cd40l的组合物和应用方法
GB0614093D0 (en) 2006-07-14 2006-08-23 Bae Systems Plc Deployable antenna system
EP2102241A2 (en) * 2006-12-15 2009-09-23 Ablynx N.V. Amino acid sequences that modulate the interaction between cells of the immune system
CN105936648B (zh) * 2008-07-18 2020-06-16 百时美施贵宝公司 Cd28结合为单价的组合物及使用方法
CA2732423A1 (en) 2008-08-21 2010-02-25 Octapharma Ag Recombinantly produced human factor viii and ix
AU2015231180B2 (en) * 2014-03-19 2017-06-15 Bristol-Myers Squibb Company Methods of treating transplant rejection using a domain antibody directed against CD40L
WO2016054218A1 (en) * 2014-09-30 2016-04-07 Bristol-Myers Squibb Company Methods of treating systemic lupus erythematosus using a domain antibody directed against cd28

Also Published As

Publication number Publication date
SI2321352T1 (sl) 2016-04-29
RS58904B1 (sr) 2019-08-30
SMT201900367T1 (it) 2019-09-09
DK2321352T3 (en) 2016-04-04
PE20140852A1 (es) 2014-07-14
CN105936648A (zh) 2016-09-14
TW201336510A (zh) 2013-09-16
US8168759B2 (en) 2012-05-01
EA024585B1 (ru) 2016-10-31
EA201100239A1 (ru) 2011-10-31
JP2011528551A (ja) 2011-11-24
AU2009270726A1 (en) 2010-01-21
JP2016063830A (ja) 2016-04-28
CA2731220A1 (en) 2010-01-21
CA2731220C (en) 2017-10-10
IL210413A (en) 2017-04-30
HRP20160329T1 (hr) 2016-04-22
US20120201814A1 (en) 2012-08-09
US8454959B2 (en) 2013-06-04
LT2700651T (lt) 2019-06-25
SMT201600090B (it) 2016-04-29
US10919965B2 (en) 2021-02-16
IL210413A0 (en) 2011-03-31
US20210047414A1 (en) 2021-02-18
CN102159590A (zh) 2011-08-17
CO6341641A2 (es) 2011-11-21
TW201006494A (en) 2010-02-16
HK1155178A1 (zh) 2012-05-11
IL251320A0 (en) 2017-05-29
JP5876134B2 (ja) 2016-03-02
PT2321352E (pt) 2016-03-18
ME02396B (me) 2016-08-31
PL2321352T3 (pl) 2016-06-30
US9908937B2 (en) 2018-03-06
JP5675608B2 (ja) 2015-02-25
ES2562629T3 (es) 2016-03-07
KR20110041527A (ko) 2011-04-21
US20150299321A1 (en) 2015-10-22
CN105936648B (zh) 2020-06-16
RS54675B1 (sr) 2016-08-31
CL2011000117A1 (es) 2011-06-17
EP2321352B1 (en) 2016-01-06
HUE045249T2 (hu) 2019-12-30
US12012452B2 (en) 2024-06-18
JP2015120695A (ja) 2015-07-02
SI2700651T1 (sl) 2019-08-30
EP2700651B1 (en) 2019-04-10
AU2009270726B2 (en) 2015-07-09
HUE029982T2 (en) 2017-04-28
HRP20190966T1 (hr) 2019-07-26
US20100028354A1 (en) 2010-02-04
NZ590343A (en) 2012-10-26
KR101660057B1 (ko) 2016-09-26
PL2700651T3 (pl) 2019-09-30
PT2700651T (pt) 2019-06-19
CL2012002428A1 (es) 2013-01-11
US9085629B2 (en) 2015-07-21
KR20160113322A (ko) 2016-09-28
EP2700651A1 (en) 2014-02-26
KR101791372B1 (ko) 2017-10-27
IL251320B (en) 2019-01-31
EP2321352A1 (en) 2011-05-18
DK2700651T3 (da) 2019-07-22
WO2010009391A1 (en) 2010-01-21
US20130109846A1 (en) 2013-05-02
JP6058833B2 (ja) 2017-01-11
ES2730727T3 (es) 2019-11-12
CY1121796T1 (el) 2020-07-31
US20180142023A1 (en) 2018-05-24
MX2011000501A (es) 2011-05-23
TWI450725B (zh) 2014-09-01
AR072571A1 (es) 2010-09-08

Similar Documents

Publication Publication Date Title
PE20110385A1 (es) Anticuerpo de dominio (dab) que se une a cd28 y no reacciona en forma cruzada con ctla4
PE20142407A1 (es) Formulacion de anticuerpos
PE20140247A1 (es) Anticuerpos anti-cd38
PE20110668A1 (es) Anticuerpos anti-linfopoyetina estromal timica (anti-tslp)
PE20140218A1 (es) Composicion farmaceutica
PE20191208A1 (es) Anticuerpos anti-cd73 y usos de los mismos
AR085600A1 (es) Agentes de union biespecifica
PE20141188A1 (es) Polipeptidos anticuerpos que antagonizan cd40
PE20190201A1 (es) Receptores quimericos de flt3 y metodos de uso de los mismos
PE20121552A1 (es) Anticuerpos monoclonales anti cea humanizados de afinidad madura
PE20110345A1 (es) Anticuerpos contra la il17 humana
PE20120341A1 (es) Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t
PE20141432A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
PE20141564A1 (es) Moleculas de union para bcma y cd3
PE20140814A1 (es) Anticuerpos contra la angiopoyetina 2 humana
ES2570153T3 (es) Anticuerpos anti-C5aR con propiedades mejoradas
PE20120415A1 (es) Anticuerpos anti-igf
PE20241623A1 (es) Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos
PE20180502A1 (es) Composiciones anti-cgrp y uso de las mismas
NZ623319A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
PE20081478A1 (es) Anticuerpos cd44
ES2572177T3 (es) Anticuerpos neutralizantes anti-B7RP1 humanos
PE20130479A1 (es) Anticuerpos reactivos con b7-h3, fragmentos inmulogicamente activos de los mismos y usos de los mismos
PE20110802A1 (es) Un anticuerpo antagonista de pcsk9
PE20090329A1 (es) Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos

Legal Events

Date Code Title Description
FG Grant, registration